NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

唾液過多 (流涎症) - 市場考察,流行病學,市場預測:2028年

Sialorrhea - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 923107
出版日期 按訂單生產 內容資訊 英文 149 Pages
商品交期: 2-10個工作天內
價格
唾液過多 (流涎症) - 市場考察,流行病學,市場預測:2028年 Sialorrhea - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 149 Pages
簡介

主要7個國家 (美國,德國,西班牙,義大利,法國,英國,日本)的唾液過多 (流涎症) 市場在2017年估算達到10億7362萬美元,預計在預測期內也將增長。美國佔最大的市場規模。

本報告提供全球唾液過多 (流涎症) 治療藥市場相關調查分析,提供疾病的背景,流行病學,主要7個國家的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 唾液過多 (流涎症) 市場概要

  • 2017年的唾液過多 (流涎症)的市場佔有率 (%) - 主要7個國家
  • 2028年的唾液過多 (流涎症)的市場佔有率 (%) - 主要7個國家

第3章 疾病的背景和概要

  • 簡介
  • 唾液過多 (流涎症)的分類
  • 唾液過多 (流涎症)的病因
  • 唾液過多 (流涎症) 相關的危險因素
  • 唾液功能的生理
  • 唾液過多 (流涎症)的病理生理學
  • 並發症被認為是唾液分泌過多的臨床特徵
  • 唾液過多 (流涎症)的評估

第4章 流行病學和患者族群

  • 主要調查結果
  • 主要7個國家的唾液過多 (流涎症)的病例數

第5章 各國流行病學

  • 美國
  • EU5個國家
  • 日本

第6章 治療和管理

  • 兒童的治療
  • 氯氮平引起的過度唾液分泌(唾液分泌)的治療
  • 帕金森氏症的唾液過多 (流涎症)的治療
  • 患者進度

第7章 未滿足需求

第8章 案例研究

  • Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report
  • 兒童患者的慢性唾液過多 (流涎症)的外科管理

第9章 上市產品

  • Cuvposa:Merz Pharmaceuticals
  • Sialanar (glycopyrronium bromide) :Proveca Pharma Ltd

第10章 新興藥

  • Myobloc:US WorldMeds
  • Xeomin (incobotulinumtoxinA) :Merz Pharma
  • NH004:NeuroHealing Pharmaceuticals

第11章 其他臨床候補

  • OP-014 (clonidine/oxybutynin) :Orient Pharma
  • NT0502:Neos Therapeutics

第12章 非適應症藥

第13章 唾液過多 (流涎症) :主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的唾液過多 (流涎症)的市場規模
  • 市場預測:主要7個國家

第14章 美國市場預測

  • 美國的市場規模

第15章 EU5個國家:市場預測

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第16章 日本:市場預測

  • 日本的市場規模
  • 唾液過多 (流涎症)的整體市場規模
  • 市場規模:不同治療

第17章 推動市場要素

第18章 市場障礙

第19章 附錄

第20章 DelveInsight的功能

第21章 免責事項

第22章 關於DelveInsight

目錄
Product Code: DIMI0635

DelveInsight's Sialorrhea- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sialorrhea in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sialorrhea from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Sialorrhea- Disease Understanding and Treatment Algorithm

Sialorrhea, also known as hypersalivation or ptyalism, is excessive salivation associated with neurological disorders or localized anatomical abnormalities in the oral cavity. Sialorrhea can be classified as anterior and posterior; both can occur separately or simultaneously. Posterior sialorrhea is the flowing of saliva from the tongue to the pharynx. Anterior sialorrhea results in salivary incontinence or involuntary spillage of saliva over the lower lip, known as drooling. The underlying etiology is the excessive production of saliva or inability to retain saliva within the mouth due to reduced neuromuscular control of the tongue, oral tissues, and impairment in the swallowing mechanism, all of which are necessary to move saliva from the oral cavity to the oropharynx and beyond.

The DelveInsight Sialorrhea market report gives the thorough understanding of the Sialorrhea by including details such as disease definition, classification, symptoms, etiology, associated risk factors, pathophysiology, clinical features and diagnostic trends. It also provides treatment algorithms and management approaches for Sialorrhea in the US, Europe and Japan.

Sialorrhea Epidemiology

The Sialorrhea epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Epidemiology of Sialorrhea Associated Etiologies, Occurrence of Sialorrhea, Occurrence of Chronic Sialorrhea) scenario of Sialorrhea in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight estimate, there were 2,484,780 cases of Sialorrhea in 7MM in 2017.Sialorrhea Drug Chapters

This segment of the Sialorrhea report encloses the detailed analysis of marketed drugs late stage (Phase-III and Phase-II) pipeline drugs along with other clinical candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, advantages and disadvantages of each included drug and the latest news and press releases.

Anticholinergics and botulinum dominate the Sialorrhea treatment landscape and therefore generate revenue. Most medications that are used to reduce saliva production have anticholinergic action at the muscarinic receptor. However, the lack of selectivity means that systemic side effects with these medications can be troublesome and impact their use. Botulinum Toxins and are increasingly being recognized as a safe and effective alternative to systemic medications for the reduction of saliva, without many of the side-effects.

Sialorrhea Market Outlook

The Sialorrhea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Sialorrhea in 7MM was found to be USD 1073.62 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Sialorrhea, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Sialorrhea Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sialorrhea Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sialorrhea Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Sialorrhea Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Sialorrhea market
  • Organize sales and marketing efforts by identifying the best opportunities for Sialorrhea market
  • To understand the future market competition in the Sialorrhea market.

Table of Contents

1. Key Insights

2. Sialorrhea Market Overview at a Glance

  • 2.1. Market Share (%) of Sialorrhea in 2017 - 7MM
  • 2.2. Market Share (%) of Sialorrhea in 2028 - 7MM

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Sialorrhea
  • 3.3. Etiology of Sialorrhea
  • 3.4. Sialorrhea associated risk factors
  • 3.5. Physiology of salivary function
  • 3.6. Pathophysiology of Sialorrhea
  • 3.7. Clinical Features and Possible Complications of Sialorrhea
  • 3.8. Assessment of Sialorrhea

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Cases of Sialorrhea in 7MM

5. Country Wise-Epidemiology

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States
    • 5.1.3. Occurrence of Sialorrhea in the United States
    • 5.1.4. Occurrence of Chronic Sialorrhea in the United States
  • 5.2. EU-5
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. United Kingdom
  • 5.3. Japan
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan
    • 5.3.3. Occurrence of Sialorrhea in Japan
    • 5.3.4. Occurrence of Chronic Sialorrhea in Japan

6. Treatment and Management

  • 6.1. Treatment for Children
  • 6.2. Treatment for Clozapine-induced Sialorrhea
  • 6.3. Treatment of Sialorrhea in Parkinson's disease
  • 6.4. Patient Journey

7. Unmet Needs

8. Case Studies

  • 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report
  • 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution

9. Marketed Products

  • 9.1. Cuvposa: Merz Pharmaceuticals
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile

10. Emerging Drugs

  • 10.1. Key Cross Competition
  • 10.2. Myobloc: US WorldMeds
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma
    • 10.3.1. Product Description
    • 10.3.2. Product Development Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. NH004: NeuroHealing Pharmaceuticals
    • 10.4.1. Product Description
    • 10.4.2. Product Development Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Safety and Efficacy
    • 10.4.5. Product Profile

11. Other Clinical Candidates

  • 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma
    • 11.1.1. Product Description
    • 11.1.2. Clinical Development
    • 11.1.3. Product Profile
  • 11.2. NT0502: Neos Therapeutics
    • 11.2.1. Product Description
    • 11.2.2. Product Development Activities
    • 11.2.3. Product Profile

12. Off label Drugs

13. Sialorrhea: 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Sialorrhea in 7MM
  • 13.3. Market Outlook: 7MM

14. The United States Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Sialorrhea
    • 14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Germany
    • 15.1.1. Total Market size of Sialorrhea in Germany
    • 15.1.2. Market Size by Therapies
  • 15.2. France
    • 15.2.1. Total Market Size of Sialorrhea
    • 15.2.2. Market Size by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market Size of Sialorrhea
    • 15.3.2. Market Size by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market Size of Sialorrhea
    • 15.4.2. Market Size by Therapies
  • 15.5. The United Kingdom
    • 15.5.1. Total Market Size of Sialorrhea
    • 15.5.2. Market Size by Therapies

16. Japan: Market Outlook

  • 16.1. Japan Market Size
  • 16.2. Total Market Size of Sialorrhea
  • 16.3. Market Size by Therapies

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

1. Key Insights

2. Sialorrhea Market Overview at a Glance

  • 2.1. Market Share (%) of Sialorrhea in 2017 - 7MM
  • 2.2. Market Share (%) of Sialorrhea in 2028 - 7MM

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Sialorrhea
  • 3.3. Etiology of Sialorrhea
  • 3.4. Sialorrhea associated risk factors
  • 3.5. Physiology of salivary function
  • 3.6. Pathophysiology of Sialorrhea
  • 3.7. Clinical Features and Possible Complications of Sialorrhea
  • 3.8. Assessment of Sialorrhea

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Cases of Sialorrhea in 7MM

5. Country Wise-Epidemiology

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States
    • 5.1.3. Occurrence of Sialorrhea in the United States
    • 5.1.4. Occurrence of Chronic Sialorrhea in the United States
  • 5.2. EU-5
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. United Kingdom
  • 5.3. Japan
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan
    • 5.3.3. Occurrence of Sialorrhea in Japan
    • 5.3.4. Occurrence of Chronic Sialorrhea in Japan

6. Treatment and Management

  • 6.1. Treatment for Children
  • 6.2. Treatment for Clozapine-induced Sialorrhea
  • 6.3. Treatment of Sialorrhea in Parkinson's disease
  • 6.4. Patient Journey

7. Unmet Needs

8. Case Studies

  • 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report
  • 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution

9. Marketed Products

  • 9.1. Cuvposa: Merz Pharmaceuticals
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile

10. Emerging Drugs

  • 10.1. Key Cross Competition
  • 10.2. Myobloc: US WorldMeds
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma
    • 10.3.1. Product Description
    • 10.3.2. Product Development Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. NH004: NeuroHealing Pharmaceuticals
    • 10.4.1. Product Description
    • 10.4.2. Product Development Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Safety and Efficacy
    • 10.4.5. Product Profile

11. Other Clinical Candidates

  • 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma
    • 11.1.1. Product Description
    • 11.1.2. Clinical Development
    • 11.1.3. Product Profile
  • 11.2. NT0502: Neos Therapeutics
    • 11.2.1. Product Description
    • 11.2.2. Product Development Activities
    • 11.2.3. Product Profile

12. Off label Drugs

13. Sialorrhea: 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Sialorrhea in 7MM
  • 13.3. Market Outlook: 7MM

14. The United States Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Sialorrhea
    • 14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Germany
    • 15.1.1. Total Market size of Sialorrhea in Germany
    • 15.1.2. Market Size by Therapies
  • 15.2. France
    • 15.2.1. Total Market Size of Sialorrhea
    • 15.2.2. Market Size by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market Size of Sialorrhea
    • 15.3.2. Market Size by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market Size of Sialorrhea
    • 15.4.2. Market Size by Therapies
  • 15.5. The United Kingdom
    • 15.5.1. Total Market Size of Sialorrhea
    • 15.5.2. Market Size by Therapies

16. Japan: Market Outlook

  • 16.1. Japan Market Size
  • 16.2. Total Market Size of Sialorrhea
  • 16.3. Market Size by Therapies

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

  • Table 1: Objective methods to measure Sialorrhea
  • Table 2: Objective methods to measure Sialorrhea
  • Table 3: Total Population of Sialorrhea in 7MM (2017-2028)
  • Table 4: Epidemiology of Sialorrhea Associated Etiologies in the United States (2017-2028)
  • Table 5: Occurrence of Sialorrhea in the United States (2017-2028)
  • Table 6: Occurrence of Chronic Sialorrhea in the United States (2017-2028)
  • Table 7: Epidemiology of Sialorrhea Associated Etiologies in Germany (2017-2028)
  • Table 8: Occurrence of Sialorrhea in Germany (2017-2028)
  • Table 9: Occurrence of Chronic Sialorrhea in Germany (2017-2028)
  • Table 10: Epidemiology of Sialorrhea Associated Etiologies in France (2017-2028)
  • Table 11: Occurrence of Sialorrhea in France (2017-2028)
  • Table 12: Occurrence of Chronic Sialorrhea in France (2017-2028)
  • Table 13: Epidemiology of Sialorrhea Associated Etiologies in Italy (2017-2028)
  • Table 14: Occurrence of Sialorrhea in Italy (2017-2028)
  • Table 15: Occurrence of Chronic Sialorrhea in Italy (2017-2028)
  • Table 16: Epidemiology of Sialorrhea Associated Etiologies in Spain (2017-2028)
  • Table 17: Occurrence of Sialorrhea in Spain (2017-2028)
  • Table 18: Occurrence of Chronic Sialorrhea in Spain (2017-2028)
  • Table 19: Epidemiology of Sialorrhea Associated Etiologies in the United Kingdom (2017-2028)
  • Table 20: Occurrence of Sialorrhea in the United Kingdom (2017-2028)
  • Table 21: Occurrence of Chronic Sialorrhea in the United Kingdom (2017-2028)
  • Table 22: Epidemiology of Sialorrhea Associated Etiologies in Japan (2017-2028)
  • Table 23: Occurrence of Sialorrhea in Japan (2017-2028)
  • Table 24: Occurrence of Chronic Sialorrhea in Japan (2017-2028)
  • Table 25: Surgical treatment of droolingsialorrhea
  • Table 26: Xeomin, Clinical Trial Description, 2019
  • Table 27: NH004, Clinical Trial Description, 2019
  • Table 28: OP-014, Clinical Trial Description, 2019
  • Table 29: Comparison of different off label anti-cholinergic medications
  • Table 30: Suggested dosages for the management of drooling with botulinum toxin
  • Table 31: 7 Major Market Size of Sialorrhea in USD Million (2017-2028)
  • Table 32: United States Market Size of Sialorrhea in the US, USD Million (2017-2028)
  • Table 33: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028)
  • Table 34: Germany Market Size of Sialorrhea in Germany, USD Million (2017-2028)
  • Table 35: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028)
  • Table 36: France Market Size of Sialorrhea in France, USD Million (2017-2028)
  • Table 37: Market Size of Sialorrhea by Therapies in France, in USD Million (2017-2028)
  • Table 38: Italy Market Size of Sialorrhea in Italy, USD Million (2017-2028)
  • Table 39: Market Size of Sialorrhea by Therapies in Italy, in USD Million (2017-2028)
  • Table 40: Spain Market Size of Sialorrhea in Spain, USD Million (2017-2028)
  • Table 41: Market Size of Sialorrhea by Therapies in Spain, in USD Million (2017-2028)
  • Table 42: UK Market Size of Sialorrhea in UK, USD Million (2017-2028)
  • Table 43: Market Size of Sialorrhea by Therapies in UK, in USD Million (2017-2028)
  • Table 44: Japan Market Size of Sialorrhea in Japan, USD Million (2017-2028)
  • Table 45: Market Size of Sialorrhea by Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Etiology of Sialorrhea
  • Figure 2: Etiology of Sialorrhea
  • Figure 3: Reflex secretion of saliva from major salivary glands
  • Figure 4: Possible pathophysiology of drooling in Parkinson's disease
  • Figure 5:Interaction between the clinical aspects involved in the health of children with CP
  • Figure 6: Total Population of Sialorrhea in 7 MM (2017-2028)
  • Figure 7: Epidemiology of Sialorrhea Associated Etiologies in the United States (2017-2028)
  • Figure 8: Occurrence of Sialorrhea in the United States (2017-2028)
  • Figure 9: Occurrence of Chronic Sialorrhea in the United States (2017-2028)
  • Figure 10: Epidemiology of Sialorrhea Associated Etiologies in Germany (2017-2028)
  • Figure 11: Occurrence of Sialorrhea in Germany (2017-2028)
  • Figure 12: Prevalence of Chronic Sialorrhea in Germany (2017-2028)
  • Figure 13: Epidemiology of Sialorrhea Associated Etiologies in France (2017-2028)
  • Figure 14: Occurrence of Sialorrhea in France (2017-2028)
  • Figure 15: Occurrence of Chronic Sialorrhea in France (2017-2028)
  • Figure 16: Epidemiology of Sialorrhea Associated Etiologies in Italy (2017-2028)
  • Figure 17: Occurrence of Sialorrhea in Italy (2017-2028)
  • Figure 18: Occurrence of Chronic Sialorrhea in Italy (2017-2028)
  • Figure 19: Epidemiology of Sialorrhea Associated Etiologies in Spain (2017-2028)
  • Figure 20: Occurrence of Sialorrhea in Spain (2017-2028)
  • Figure 21: Occurrence of Chronic Sialorrhea in Spain (2017-2028)
  • Figure 22: Epidemiology of Sialorrhea Associated Etiologies in the United Kingdom (2017-2028)
  • Figure 23: Occurrence of Sialorrhea in the United Kingdom (2017-2028)
  • Figure 24: Occurrence of Chronic Sialorrhea in the United Kingdom (2017-2028)
  • Figure 25: Epidemiology of Sialorrhea Associated Etiologies in Japan (2017-2028)
  • Figure 26: Occurrence of Sialorrhea in Japan (2017-2028)
  • Figure 27: Occurrence of Chronic Sialorrhea in Japan (2017-2028)
  • Figure 28: Mechanism of action of BoNT along with that of normal cell
  • Figure 29: Treatment algorithm for treating Sialorrhea
  • Figure 30: Treatment algorithm for treating Sialorrhea in children
  • Figure 31: Patient Journey for Sialorrhea
  • Figure 32: Unmet Needs for Sialorrhea
  • Figure 33: 7 Major Market Size of Sialorrhea in USD Million (2017-2028)
  • Figure 34: Market Size of Sialorrhea in the United States, USD Millions (2017-2028)
  • Figure 35: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028)
  • Figure 36: Market Size of Sialorrhea in Germany, USD Millions (2017-2028)
  • Figure 37: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028)
  • Figure 38: Market Size of Sialorrhea in the France, USD Millions (2017-2028)
  • Figure 39: Market Size of Sialorrhea by Therapies in France, in USD Million (2017-2028)
  • Figure 40: Market Size of Sialorrhea in Italy, USD Millions (2017-2028)
  • Figure 41: Market Size of Sialorrhea by Therapies in Italy, in USD Million (2017-2028)
  • Figure 42: Market Size of Sialorrhea in the Spain, USD Millions (2017-2028)
  • Figure 43: Market Size of Sialorrhea by Therapies in Spain, in USD Million (2017-2028)
  • Figure 44: Market Size of Sialorrhea in the UK, USD Millions (2017-2028)
  • Figure 45: Market Size of Sialorrhea by Therapies in UK, in USD Million (2017-2028)
  • Figure 46: Market Size of Sialorrhea in Japan, USD Millions (2017-2028)
  • Figure 47: Market Size of Sialorrhea by Therapies in Japan, in USD Million (2017-2028)
  • Figure 48: Market Drivers for Sialorrhea
  • Figure 49: Market Barriers for Sialorrhea